LEXINGTON, Mass., July 15, 2013 /PRNewswire/ -- Virtify, Inc., a leading innovator in content and regulatory information management solutions for the life science industry, today announced that Sarah Cannon Research Institute (SCRI), a wholly owned subsidiary of HCA, has signed an enterprise-level contract for its Clinical Trial Registration & Results (CTRR) disclosure software. SCRI will utilize Virtify's CTRR to disclose their clinical trial information to the National Institute of Health's clinicaltrials.gov system as mandated by federal regulation.
The old paradigm for managing disclosure throughout the clinical trial process has changed, including at academic and research organizations. Many now recognize that the large number of disparate, investigator-driven studies at these institutions, coupled with constant updates to these studies and increasingly complex disclosure requirements, render manual processes too cumbersome and error-prone.
"Sarah Cannon Research Institute is pleased to partner with Virtify to help automate the clinical trial disclosure processes within the SCRI Services Organization in order to fulfill its regulatory requirements," said Sheetal Khedkar, M.D., M.S.P.H, Director for Pharmacovigilance, Medical Writing and Scientifics at SCRI. "Virtify CTRR will help automate registration and results posting, significantly reducing the effort it takes to publish the trial information to clinicaltrials.gov."
Virtify's CTRR software helps streamline and automate the mandatory registration and results disclosure postings to the clinicaltrials.gov website and to other registries. The software also has the ability to provide a compliance view across all studies at an institution, allowing for better reporting and proactive comp
|SOURCE Virtify, Inc.|
Copyright©2012 PR Newswire.
All rights reserved